MPT Foundation

Who we are

My Personal Therapeutics Foundation 

Introduction:

My Personal Therapeutics Foundation’s mission is to bring personalized drug therapy to everyone regardless of their financial capabilities. Giving “help and hope” to people affected by cancer and other rare genetic conditions.

MPT Foundation is a corporate foundation with MPT Ltd. as its philanthropic parent company which is revolutionising personalised drug discovery and recommendation for patients worldwide. 

About MPT Ltd:

My Personal Therapeutics identifies drug treatments for patients based on their tumor genetics. They are training AI algorithms using highly precise data derived from and validated by their comprehensive drug testing. They employ a proprietary, low-cost, whole animal (drosophila) model that recapitulates an individual’s unique cancer genetics and faithfully models tumour-host interactions. MPT’s licensor, Mount Sinai, has used this platform to treat very difficult cases (e.g., KRAS+ metastatic colorectal cancer) with highly precise personalized combinations of FDA-approved drugs including unexpected compounds. Nearly all combinations incorporate non-cancer drugs, making them less toxic and more affordable.

As with all exponential technologies, MPT’s database and AI algorithm will grow and improve with collective patient experience. They are working to build our TuMatch databases intelligently.

What is TuMATCH?

MPT are developing TuMatch, an AI powered service, which will suggest treatment options for a patient’s specific tumour genetics. Based on Mount Sinai’s results, they expect that data from a few hundred patients per tumour type will be needed to operationalize TuMatch.

To feed TuMatch, MPT offers two types of drug screening: Personal Discovery Process

(PDP), which evaluates >1,500 drug treatments over 8 months and targeted PDP (tPDP), which evaluates ~200 drug treatments over 5-6 months.

Their patient avatars will help drug companies identify genotypes where their proprietary drugs are effective, enabling better patient stratification, clinical trial design and recruitment. MPT will develop TuMatch for all tumour types with a significant genetic cause. They are initially focusing on colorectal and breast cancer as they are largely unresponsive to immunotherapy and manifest deep genetically driven pockets of resistance.

Where does MPT Foundation fit in?

UK has been on the foreground of many scientific breakthroughs. There are many opportunities available in UK through grants funding and research that makes London a great choice to setup. MPT Ltd. has worked hard to minimize the cost of PDP but realize that still it isn't affordable for most. The financial burden of battling cancer can be overwhelming as it is, not everyone can afford it. Thus, we created the My Personal Therapeutics Foundation to address this gap.

Through our influencing and campaigning work, MPT Foundation will support everything that MPT Ltd. is doing, by making it accessible and affordable for masses.

MPT Foundation’s strategy is to grow our international profile in all our activities through targeting oncology centres by networking and collaborating with knowledge sharing around PDP. Focus will be given to patients who can benefit from the personalised drug recommendation and have exhausted all other drug treatment options. If they can’t afford it, we will fund their PDP/tPDP through the MPT foundation. Not only we would like to provide access to personalized therapeutics to all individuals but in doing so it serves another purpose; MPT’s TuMatch database is enriched by tumour genomic data from wider range of population from different ethnic and racial backgrounds.

This collaborative relationship between company and foundation will give us a strong foothold for fundraising. This strategy will enable us to join all our activities together to improve our national profile, increase income and enable us to spend more on our research, support and prevention activities across the globe.